Skip to contentD
Decoy Therapeutics Inc.
D
DCOYDecoy Therapeutics Inc. Q3 2018 · 10-Q
Revenue$469.05K$469.05K+13.4% vs Q3 2017 Net Income-$307.45K-$307.45KN/M vs Q3 2017 EPS Diluted-$0.20-$0.20N/M vs Q3 2017 Operating Income-$313,514N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Decoy Therapeutics Inc. · CIK 1615219 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$21,457,574N/M Margins · derivedOperating margin-66.8%+2208.2 pt vs Q3 2017
Net margin-65.5%+2190.8 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 5, 2018 · 36 d after period end